Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing
AstraZeneca (LON:AZN) and Alexion collaborate with the FDA to broaden the US label for Ultomiris.
AstraZeneca PLC (LON: AZN) announced that the US Food and Drug Administration (FDA) has requested a risk assessment and mitigation strategy in response to a proposal to broaden the application
AstraZeneca subsidiary finalizes a US$1bn deal with Pfizer for rare diseases.
AstraZeneca has reported a stronger-than-anticipated performance in the second quarter, with robust sales from its leading cancer drugs offsetting the decline in Covid vaccine sales.
Remote Monitored Sys (RMS.L) Anglo-Indian Pro-Larva mask partnership
The Board of RMS acknowledges the press release announced today by the British High Commission regarding its Anglo-Indian partnership to distribute its MHRA approved Pro-Larva mask in India:
Remote Monitored Sys (RMS.L) Result of AGM – Name Change
The Company is pleased to announce that all the resolutions that were put to shareholder at the Company’s annual general meeting (“AGM”) earlier today were passed. The votes cast for
Remote Monitored Sys (RMS.L) AGM Statement
Antony Legge, Executive Chairman of RMS, will make the following statement at today’s annual general meeting:
Remote Monitored Sys (RMS.L) Shareholders’ Questions and Answers
The Company has today placed on its website a list of questions from shareholders together with answers.
Remote Monitored Sys (RMS.L) Update on new product development
The Company is pleased to announce that the 5-ply version of its Pro-Larva anti-viral mask, developed with Volz Filters UK Ltd (“Volz”), has been approved by the UK’s Medicines and
Pharm2Farm: Revolutionary Anti-viral face mask kills 99.9% of Covid-19 virus on contact
New Pro-Larva mask incorporates unique British copper nanoparticle technology to create a virucidal barrier effective against Covid-19 and other viruses, including influenza
Antony Legge, Interim Executive Chairman, Remote Monitored Systems (RMS.L) Interview
Finally, we got the opportunity to speak with Antony about today company update and ask a few questions we hope shareholders find informative. What is cleary stated, P2F’s company portfolio
Remote Monitored Sys (RMS.L) Update on Pharm to Farm Ltd
The Company is pleased to report the significant progress achieved since the announcement on 18 February.